Valuation: Orgenesis Inc.

Market Cap 985K 882K 812K 735K 1.37M 93.55M 1.4M 9.68M 3.89M 49.21M 3.7M 3.62M 155M P/E 2023
-0.26x
P/E 2024 -0.17x
Enterprise Value 19.17M 17.17M 15.79M 14.31M 26.74M 1.82B 27.24M 188M 75.59M 957M 71.93M 70.4M 3.02B EV / Sales 2023
71.2x
EV / Sales 2024 27x
Free-Float
52.06%
Yield 2023 *
-
Yield 2024 -
1 day+181.25%
1 week+12.50%
Current month+1,504.28%
1 month-18.18%
3 months-36.62%
6 months+12.50%
Current year+200.00%
1 week 0
Extreme 0.001
0.45
1 month 0
Extreme 0.0001
0.58
Current year 0
Extreme 0.0001
0.84
1 year 0
Extreme 0.0001
0.91
3 years 0
Extreme 0.0001
10.8
5 years 0
Extreme 0.0001
52
10 years 0
Extreme 0.0001
168
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 72 01/02/2012
Chief Executive Officer 57 23/12/2013
Director of Finance/CFO 51 09/03/2026
Director TitleAgeSince
Chairman 57 13/08/2014
Director/Board Member 64 07/07/2024
Director/Board Member 47 27/10/2024
Date Insider Type Main position Quantity % Market Cap. Importance
05/03/25 Other 1,200,000 23.2142%
12/12/24 Free

Director

1,500 0.0290%
12/12/24 Free

Director

1,835 0.0355%
Change 5-day change 1-year change 3-year change Capi.($)
+181.25%+12.50%+200.00%-93.38% 275K
+1.56%+2.41%-14.09%+12.32% 184B
-0.59%+1.18%+6.44%+36.82% 118B
-6.38%-4.98%-18.07%+8.01% 111B
+3.42%+1.71%-41.92%+8.01% 94.58B
+0.09%-0.05%-2.06%+78.69% 63.13B
-0.46%+0.42%+4.48%+82.84% 55.66B
-0.23%-0.52%+10.73%-21.72% 53.9B
-4.30%-1.64%-12.44%+37.99% 43.42B
+0.58%+2.00%-1.17%-8.82% 34.68B
Average +17.49%+0.05%+13.19%+14.07% 75.84B
Weighted average by Cap. -0.48%+0.24%-10.13%+23.75%

Financials

2023 2024
Net sales 530K 475K 437K 396K 739K 50.32M 753K 5.21M 2.09M 26.47M 1.99M 1.95M 83.48M 1.03M 927K 853K 773K 1.44M 98.27M 1.47M 10.17M 4.08M 51.69M 3.88M 3.8M 163M
Net income -55.36M -49.58M -45.61M -41.32M -77.24M -5.26B -78.69M -544M -218M -2.77B -208M -203M -8.72B -48.16M -43.14M -39.68M -35.95M -67.2M -4.57B -68.46M -473M -190M -2.41B -181M -177M -7.59B
Net Debt 21.78M 19.51M 17.95M 16.26M 30.39M 2.07B 30.96M 214M 85.91M 1.09B 81.75M 80.01M 3.43B 18.18M 16.28M 14.98M 13.57M 25.37M 1.73B 25.84M 179M 71.7M 908M 68.23M 66.78M 2.86B
Projected Income Statement - Annual - Orgenesis Inc.
Logo Orgenesis Inc.
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Employees
77
Date Price Change Volume
30/10/26 US$0.0281 -39.94% 6,300
27/10/26 US$0.0467 -86.66% 2,611
26/10/26 US$0.3500 -12.50% 7,400
  1. Stock Market
  2. Stocks
  3. ORGS Stock